A Phase 2, Randomized, Sham-Controlled, Single-Masked, Dose-Ranging, Multi-Center Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Macula-off Rhegmatogenous Retinal Detachment

The goal of this Phase 2 clinical trial is to learn about ONL1204 Ophthalmic Solution in terms of safety and how well the drug works in patients that have a macula-off (central point of vision) rhegmatogenous retinal detachment (RRD). The main questions it aims to answer are:
Does ONL1204 improve vision in macula-off RRD patients when used before retinal detachment repair surgery compared to patients that have surgery alone?
Is ONL1204 safe to use as an add-on drug before retinal repair surgery?
Researchers will observe patients that receive two different dosages of ONL1204 Ophthalmic Solution (50 µg or 200 µg) compared to current standard therapy (no treatment) to see if there are differences in vision and safety outcomes.

开始日期2023-04-04

申办/合作机构

ONL Therapeutics, Inc.

NCT05160805 / Active, not recruiting临床1期

A Phase 1b Multicenter, Randomized, Single-Masked, Sham-Controlled Study of the Safety and Tolerability of ONL1204 Ophthalmic Solution in Patients With Progressing Open Angle Glaucoma

The purpose of this study is to demonstrate the safety and tolerability of ONL1204 Ophthalmic Solution in patients with progressing open angle glaucoma.
ONL1204 Ophthalmic Solution is a first-in-class inhibitor of fragment apoptosis stimulator (Fas) receptor-mediated cell death that has demonstrated protection of multiple retinal cell types in numerous preclinical models of retinal disease. Apoptosis of retinal ganglion cells is associated with progressive glaucoma. Nonclinical data on ONL1204 Ophthalmic Solution suggest that ONL1204 Ophthalmic Solution may inhibit the cell death pathways in these cells.

开始日期2022-05-02

申办/合作机构

ONL Therapeutics, Inc.

NCT04744662 / Completed临床1期

A Phase 1b Multicenter, Randomized, Controlled, Single-dose Study of the Safety and Tolerability of ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy (GA) Associated With Age-related Macular Degeneration (AMD

The purpose of this study is to evaluate the safety and tolerability of intravitreal injection of ONL1204 Ophthalmic Solution in patients with geographic atrophy associated with AMD.
GA associated with AMD is one of the world's leading causes of visual disability. It is a progressive disease with no approved therapy to slow or arrest the process of continual photoreceptor and retinal epithelial (RPE) cell loss. A safe and effective therapy for GA will have vast societal benefits. ONL1204 is being developed for this purpose. ONL1204 is a first-in-class inhibitor of fragment apoptosis stimulator receptor-mediated cell death in development for to reduce rates of vision in patients with GA associated with AMD. ONL1204 has demonstrated protection of multiple retinal cell types in several preclinical models of acute ocular injury and the protection of RPE in AMD models. ONL1204 Ophthalmic Solution is currently in a Phase 1 clinical study in patients with macula-off retinal detachment to evaluate safety and tolerability of a single-dose of ONL1204 Ophthalmic Solution. The study is ongoing and uses the same doses and route of administration as this Phase 1b study in patients with GA.

开始日期2021-07-08

申办/合作机构

ONL Therapeutics, Inc.

100 项与 ONL-1204 相关的临床结果

登录后查看更多信息

100 项与 ONL-1204 相关的转化医学

登录后查看更多信息

100 项与 ONL-1204 相关的专利（医药）

登录后查看更多信息

项与 ONL-1204 相关的文献（医药）

2019-12-01·Journal of neuroinflammation1区 · 医学

A small peptide antagonist of the Fas receptor inhibits neuroinflammation and prevents axon degeneration and retinal ganglion cell death in an inducible mouse model of glaucoma

1区 · 医学

ArticleOA

作者: Kocab, Andrew J ; Marshak-Rothstein, Ann ; Zacks, David N ; Krishnan, Anitha ; Gregory-Ksander, Meredith

Abstract:

Background:

Glaucoma is a complex, multifactorial disease where apoptosis, microglia activation, and inflammation have been linked to the death of retinal ganglion cells (RGCs) and axon degeneration. We demonstrated previously that FasL-Fas signaling was required for axon degeneration and death of RGCs in chronic and inducible mouse models of glaucoma and that Fas activation triggered RGC apoptosis, glial activation, and inflammation. Here, we investigated whether targeting the Fas receptor with a small peptide antagonist, ONL1204, has anti-inflammatory and neuroprotective effects in a microbead-induced mouse model of glaucoma.

Methods:

Intracameral injection of microbeads was used to elevate intraocular pressure (IOP) in Fas-deficient (Faslpr) mice and WT C57BL/6J mice that received an intravitreal injection of the Fas inhibitor, ONL1204 (2 μg/1 μl) (or vehicle only), on day 0 or day 7 after microbead injection. The IOP was monitored by rebound tonometry, and at 28 days post-microbead injection, Brn3a-stained RGCs and paraphenylenediamine (PPD)-stained axons were analyzed. The effects of ONL1204 on retinal microglia activation and the expression of inflammatory genes were analyzed by immunostaining of retinal flatmounts and quantitative PCR (qPCR).

Results:

Rebound tonometry showed equivalent elevation of IOP in all groups of microbead-injected mice. At 28 days post-microbead injection, the RGC and axon counts from microbead-injected Faslprmice were equivalent to saline-injected (no IOP elevation) controls. Treatment with ONL1204 also significantly reduced RGC death and loss of axons in microbead-injected WT mice when compared to vehicle-treated controls, even when administered after IOP elevation. Confocal analysis of Iba1-stained retinal flatmounts and qPCR demonstrated that ONL1204 also abrogated microglia activation and inhibited the induction of multiple genes implicated in glaucoma, including cytokines and chemokines (GFAP, Caspase-8, TNFα, IL-1β, IL-6, IL-18, MIP-1α, MIP-1β, MIP-2, MCPI, and IP10), components of the complement cascade (C3, C1Q), Toll-like receptor pathway (TLR4), and inflammasome pathway (NLRP3).

Conclusions:

These results serve as proof-of-principal that the small peptide inhibitor of the Fas receptor, ONL1204, can provide robust neuroprotection in an inducible mouse model of glaucoma, even when administered after IOP elevation. Moreover, Fas signaling contributes to the pathogenesis of glaucoma through activation of both apoptotic and inflammatory pathways.

Frontiers in neurology3区 · 医学

The Role of Neuroinflammation in Glaucoma: An Update on Molecular Mechanisms and New Therapeutic Options

3区 · 医学

ReviewOA

作者: Ponzetto, Antonio ; Rolle, Teresa ; Malinverni, Lorenza

Glaucoma is a multifactorial optic neuropathy characterized by the continuous loss of retinal ganglion cells, leading to progressive and irreversible visual impairment. In this minireview, we report the results of the most recent experimental studies concerning cells, molecular mechanisms, genes, and microbiome involved in neuroinflammation processes correlated to glaucoma neurodegeneration. The identification of cellular mechanisms and molecular pathways related to retinal ganglion cell death is the first step toward the discovery of new therapeutic strategies. Recent experimental studies identified the following possible targets: adenosine A2A receptor, sterile alpha and TIR motif containing 1 (neurofilament light chain), toll-like receptors (TLRs) 2 and 4, phosphodiesterase type 4 (PDE4), and FasL-Fas signaling (in particular ONL1204, a small peptide antagonist of Fas receptors), and therapies directed against them. The continuous progress in knowledge provides interesting data, although the total lack of human studies remains an important limitation. Further research is required to better define the role of neuroinflammation in the neurodegeneration processes that occur in glaucomatous disease and to discover neuroprotective treatments amenable to clinical trials. The hereinafter reviewed studies are reported and evaluated according to their translational relevance.

项与 ONL-1204 相关的新闻（医药）

2024-01-23

·GlobeNewswire-Health Care

ONL Therapeutics to Present on ONL1204 in Podium Presentation at the 47th Annual Meeting of the Macula Society

The presentation will review study population data from ONL’s Phase 2 study of ONL1204 Ophthalmic Solution in patients with Macula-Off Rhegmatogenous Retinal DetachmentANN ARBOR, Mich., Jan. 23, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, announced today that David Zacks, M.D., Ph.D., chief scientific officer and co-founder of ONL Therapeutics, and the Edna H. Perkiss Research Professor of Ophthalmology and Visual Sciences at the Kellogg Eye Center of the University of Michigan, will present an update on the company’s Phase 2 study in patients with rhegmatogenous retinal detachment (RRD) at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 – 10, 2024, at the La Quinta Resort & Club in Palm Springs, California. “We believe our Phase 2 randomized study to assess the safety and efficacy of intravitreal ONL1204 Ophthalmic Solution in patients with macula-off rhegmatogenous retinal detachment (RRD) could play an important role in treating this vision-threatening condition, and we look forward to sharing an update at the Macula Society meeting,” said David Esposito, chief executive officer of ONL Therapeutics. “With the study now fully enrolled we will focus our attention on gathering and analyzing the data with a goal to share topline results in the second quarter of 2024.” Details of the podium presentation are as follows: Title: Fas Inhibition with ONL1204 for Macula-off Rhegmatogenous Retinal Detachment (RRD): Study Population Data on a Phase 2, Multicenter, Randomized, Sham-controlled, Single-Masked, Clinical Trial Presenter: David N. Zacks, M.D., Ph.D.Chief Scientific Officer, ONL TherapeuticsEdna H. Perkiss Research Professor of Ophthalmology and Visual Sciences, Kellogg Eye CenterUniversity of Michigan Date / Time: Saturday, February 10, 2024, at 10:28 a.m. PT Session: Surgery I (Retinal Detachment) About Rhegmatogenous Retinal DetachmentRhegmatogenous retinal detachment (RRD) is an acute and serious vision-threatening condition in which a tear in the retina allows liquefied vitreous to enter the subretinal space, thereby detaching the photoreceptor (PR) layer of the retina from the retinal pigment epithelium (RPE), the principal source of metabolic support for the PR layer. Once detached, PRs undergo a cascade of inflammation and cell death leading to vision loss after RRD. There are nearly 100,000 retinal detachment repairs annually in the US alone. About ONL1204 Ophthalmic SolutionONL1204 is a novel, first-in-class small molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across a range of retinal diseases and conditions. Death of these retinal cells, through both direct and inflammatory signaling pathways, is the root cause of vision loss and the leading cause of blindness. The company’s later-stage clinical development program for ONL1204 currently includes a Phase 2 study in the U.S. for the treatment of macula-off retinal detachment (NCT05730218), a condition for which the compound has been granted orphan drug designation by the United States Food and Drug Administration (FDA). The company is also conducting a Phase 1b clinical trial in patients with geographic atrophy (GA) associated with age-related macular degeneration (AMD) (NCT04744662) and a Phase 1b clinical trial in patients with progressing open-angle glaucoma (NCT05160805) at sites in Australia and New Zealand. Preclinical work is ongoing to enable clinical trials in other disease indications, including inherited retinal degeneration (IRD; also known as retinitis pigmentosa). About ONL TherapeuticsONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to developing first-in-class therapeutics to protect and improve the vision of patients with retinal disease. By advancing a breakthrough technology designed to protect key retinal cells from Fas-mediated cell death, ONL is pioneering a new approach to preserving vision. ONL is developing a platform of products for use in a wide range of blinding diseases, including retinal detachment, glaucoma, AMD and IRD. For more information about ONL Therapeutics, please visit www.onltherapeutics.com.

临床2期孤儿药临床1期

2023-08-31

·GlobeNewswire-Health Care

ONL Therapeutics Completes Enrollment in Phase 2 Study of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment

More than 135 patients recruited in four months for Phase 2 study of a single intravitreal (IVT) injection of ONL1204 Ophthalmic Solution as adjunct to standard-of-care surgery Topline data readout expected in 1H2024 ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the completion of patient enrollment in its Phase 2 clinical trial of ONL1204 Ophthalmic Solution in patients with macula-off rhegmatogenous retinal detachment (RRD). The ongoing Phase 2 clinical trial is a randomized, controlled study designed to assess 135 patients across three arms, including two treatment groups and a sham group. The goal of the study is to evaluate the safety and efficacy of a single intravitreal (IVT) injection of ONL1204 as an adjunct to standard-of-care surgical repair in subjects with macula-off RRD at 37 sites across the United States. “Completing enrollment of over 135 patients in this U.S.-based Phase 2 study is a critical milestone as we continue our efforts to advance ONL1204 for patients suffering from retinal diseases such as RRD,” said David Esposito, chief executive officer of ONL Therapeutics. “We look forward to sharing topline results from this study in the first half of next year and to completing our Phase 1b clinical studies in the chronic indications of geographic atrophy associated with age-related macular degeneration and progressing open-angle glaucoma, both of which are being conducted at sites in Australia and New Zealand.” “We are pleased with how quickly our participating clinical sites were able to recruit for our Phase 2 RRD study. The level of enthusiasm and partnership from our sites has been tremendous as we work toward our common goal of bringing a novel neuroprotection therapy to patients suffering from RRD,” said David Zacks, M.D., Ph.D., co-founder and chief scientific officer of ONL Therapeutics. “We are extremely grateful to the patients, families and investigators involved for their dedication and commitment to this study.” About ONL1204 Ophthalmic Solution ONL1204 is a novel, first-in-class small molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across a range of retinal diseases and conditions. Death of these retinal cells, through both direct and inflammatory signaling pathways, is the root cause of vision loss and the leading cause of blindness. The company’s later-stage clinical development program for ONL1204 currently includes a Phase 2 study in the U.S. for the treatment of macula-off retinal detachment (NCT05730218), a condition for which the compound has been granted orphan drug designation by the United States Food and Drug Administration (FDA). The company is also conducting a Phase 1b clinical trial in patients with geographic atrophy (GA) associated with age-related macular degeneration (AMD) (NCT04744662) and a Phase 1b clinical trial in patients with progressing open-angle glaucoma (NCT05160805) at sites in Australia and New Zealand. Preclinical work is ongoing to enable clinical trials in other disease indications, including inherited retinal degeneration (IRD; also known as retinitis pigmentosa). About ONL Therapeutics ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to developing first-in-class therapeutics to protect and improve the vision of patients with retinal disease. By advancing a breakthrough technology designed to protect key retinal cells from Fas-mediated cell death, ONL is pioneering a new approach to preserving vision. ONL is developing a platform of products for use in a wide range of blinding diseases, including retinal detachment, glaucoma, AMD and IRD. The content above comes from the network. if any infringement, please contact us to modify.

孤儿药临床2期

2023-08-26

·动脉网

首家预防Fas介导的关键视网膜细胞凋亡公司，C轮融资1500万美元

“To help patients see the future”，ONL Therapeutics在其官网如是写道。ONL Therapeutics是一家临床阶段的生物制药公司，其愿景是帮助患有一系列视网膜疾病的患者保护并改善视力。该公司于2011年在美国密歇根州安娜堡成立。世界卫生组织（WHO）披露，眼科疾病已成为仅次于肿瘤、心血管疾病的第三位高危害及影响人们生活质量的疾病。WHO发布的首份《世界视力报告》显示，在全球22亿视力障碍患者中，保守估计至少有10亿视力障碍或失明患者的疾病本可以预防或尚未得到有效医治。其中包括未被治愈的白内障(6520万)、青光眼(690万)、角膜混浊(420万)、糖尿病视网膜病变(300万)等患者。基于其在视网膜神经保护方面的专业知识，ONL Therapeutics正在开发针对严重威胁视力的视网膜疾病的新型疗法。Fas介导的关键视网膜细胞凋亡是视力损失的根本原因、失明的主要原因，也是目前尚未得到充分满足的医疗需求。而ONL Therapeutics就是全球第一家也是唯一一家专注于预防Fas介导的关键视网膜细胞凋亡的公司。ONL Therapeutics的主要候选药物ONL1204是一种小肽Fas抑制剂，旨在保护视网膜细胞免受凋亡和炎症信号通路的影响。该公司拥有围绕Fas通路及其候选药物组成的知识产权体系。通过推进一项旨在防止因自然Fas通路激活而引起的关键视网膜细胞凋亡的突破性技术，ONL Therapeutics开创了一种全新的视力保护方法。通过抑制Fas途径，防止关键视网膜细胞的凋亡ONL Therapeutics研发工作的焦点在于Fas介导的信号传导。该信号传导由细胞表面的Fas受体激活，被认为是机体激活细胞凋亡的基石机制之一。而重要细胞的凋亡是引发许多疾病的根本原因，并且与许多眼科疾病尤为相关。Fas介导的免疫信号传导可诱导额外的细胞凋亡，增加对周围组织的损伤，并导致原本的损伤进一步恶化。其中，Fas受体指TNFSF6/FASLG的受体，又称凋亡介导表面抗原Fas和Apo-1抗原。它是一种细胞表面蛋白，与Fas配体结合后介导细胞凋亡。Fas介导的程序性细胞死亡是一种自然存在的细胞死亡途径，可以被多种因素激活，如氧化应激、炎症、缺血和外伤。当Fas途径被激活时，就会触发一系列的反应，进而导致细胞自我毁灭。Fas介导的程序性细胞死亡（包括细胞凋亡）在光感受器丧失中发挥着关键作用，而感光细胞死亡则是导致多种视网膜疾病甚至永久性视力丧失的最终原因。ONL Therapeutics已证明Fas在诱发多种视网膜疾病中发挥着重要作用，包括视网膜脱离、干性和湿性年龄相关性黄斑变性、葡萄膜炎、糖尿病性视网膜病变、青光眼和视神经病变。而抑制受体上的Fas信号传导则是防止其负面影响的最直接、最上游的方法。ONL Therapeutics认为，阻断Fas激活及其后续信号传导在治疗视网膜疾病方面具有广泛的临床价值。同时，视网膜神经保护和感光细胞生理学领域的先驱和公认的思想领袖、ONL Therapeutics联合创始人兼首席科学家David Zacks证明了Fas通路在很大程度上导致了细胞死亡，并发现了能够阻断Fas受体并保护光感受器的独特分子。于是，ONL1204应运而生。ONL1204是一种新型的小分子Fas抑制剂，也是ONL Therapeutics的主要候选药物，旨在保护包括光感受器在内的关键视网膜细胞免受一系列视网膜疾病和在此条件下发生的细胞死亡的影响。ONL1204是一种小分子肽，其作用机制是通过抑制Fas途径，防止关键视网膜细胞（如光感受器）的凋亡。ONL1204可以与Fas受体结合，阻断其与Fas配体的相互作用进而实现阻止Fas途径的激活，保护视网膜细胞免受凋亡。同时，ONL1204还可以抑制炎症信号通路，从而进一步减轻视网膜损伤。适应症范围广泛，已被FDA指定为孤儿药ONL1204可以保护多种视网膜细胞，包括感光细胞、视网膜色素上皮细胞和神经节细胞，从而延缓或阻止视力损失的进展，也可以作为辅助治疗，与现有的标准护理手术或药物相结合，提高治疗效果和视觉结果。它具有广泛的适应症范围，可以用于治疗多种严重的、可能导致失明的视网膜疾病，包括孔源性视网膜剥离（RRD）、视网膜中央动脉闭塞（CRAO）、青光眼、血管性眼病等。目前，该化合物已被美国食品药品监督管理局（FDA）指定为孤儿药。2023年4月12日，ONL Therapeutics宣布在针对黄斑孔源性视网膜脱离患者（RRD）的ONL1204 眼科溶液2期临床试验中，第一位患者已接受给药。该2期临床试验是一项随机对照研究，招募了135名患者，分为3组，包括两个治疗组和一个虚假对照组。该研究的目的是评估单次玻璃体内（IVT）注射ONL1204作为标准护理手术修复的辅助手段对美国约 30 个地区的黄斑脱落 RRD 受试者的安全性和有效性。ONL Therapeutics的联合创始人兼首席科学官David Zacks医学博士表示，这是该公司首次把ONL1204带给美国的患者和临床医生，是一个重要的里程碑，“凭借其针对Fas激活途径的独特和差异化的作用机制，我们期待着推进ONL1204的临床开发，作为一种潜在的突破性神经保护疗法，以解决包括RRD在内的许多眼科疾病领域未满足的医疗需求。”不少临床医生们认识到，在眼科疾病领域有一种未满足的重大医疗需求，即一种能够在诊断后和手术前的关键时期保护患者的感光细胞的疗法，并且该疗法应当在视网膜重新贴合后提供更好的视觉效果。“而ONL1204这一首创的神经保护剂，可以作为黄斑区视网膜脱离患者标准护理手术的辅助治疗手段，这让视网膜领域的专业人士感到振奋，”Zacks博士说。国家顶级眼科思想领袖担任科学顾问ONL Therapeutics拥有一支在药物开发和视网膜疾病方面有数十年经验的管理和专家咨询团队。其总裁兼首席执行官David Esposito是Armune BioScience的前首席执行官，他领导了基于血液的诊断技术的开发和商业化以改善癌症的早期检测，在医疗保健方面颇有经验。联合创始人兼首席科学家David Zacks是密歇根大学凯洛格眼科中心的眼科教授和临床医生科学家，在控制视网膜疾病中光感受器死亡或存活的分子调节机制方面拥有15年的经验。此外，其科学顾问委员会包含诸多国家顶级眼科思想领袖，如哈佛医学院眼科系主任兼马萨诸塞州眼耳科和麻省总医院眼科主任Joan W. Miller博士、威尔斯眼科医院临床视网膜研究室主任和视网膜外科医生兼托马斯杰斐逊大学医学院眼科教授Allen Ho等等。他们为公司提供了权威、前沿的眼科学术信息和技术指导，帮助ONL Therapeutics优化其产品开发策略和临床试验设计。2023年3月8日，ONL Therapeutics宣布已完成了1500 万美元的C轮融资。本轮投资由Visionary Venture Fund、Mayewell Capital、Bios Partners、Alpine Visionary领投，PSQ Capital、MINTS、Kaitai Capital等参投。本轮融资支持了ONL1204眼科溶液进入黄斑脱落性孔源性视网膜脱离（RRD）患者的2期临床试验，以及公司为GA和OAG第二阶段项目的监管准备工作。接下来，ONL Therapeutics将继续专注于ONL1204的临床试验。目前该公司还在澳大利亚和新西兰开展了一项针对与年龄相关性黄斑变性（AMD）相关的地图样萎缩（GA）患者的1b期临床试验（NCT04744662），以及一项针对进展期开角型青光眼患者的1b阶段临床试验（NCT05160805）。目前正在进行的临床前工作将拓展到其他疾病适应症，包括遗传性视网膜变性（IRD）的临床试验。未来，ONL Therapeutics计划进一步开发ONL1204，推进视网膜疾病领域的疗法创新，为患者提供更有效和安全的治疗方案。近期推荐声明：动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。未经许可，禁止进行转载、摘编、复制及建立镜像等任何使用。动脉网，未来医疗服务平台

100 项与 ONL-1204 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
视网膜脱离	临床2期	美国	ONL Therapeutics, Inc.	2023-04-04
孔源性视网膜脱离 - 黄斑脱落	临床2期	美国	ONL Therapeutics, Inc.	2023-04-04
开角型青光眼	临床1期	澳大利亚	ONL Therapeutics, Inc.	2022-05-02
开角型青光眼	临床1期	新西兰	ONL Therapeutics, Inc.	2022-05-02
年龄相关性黄斑变性	临床1期	澳大利亚	ONL Therapeutics, Inc.	2021-07-08
年龄相关性黄斑变性	临床1期	新西兰	ONL Therapeutics, Inc.	2021-07-08
地图样萎缩	临床1期	澳大利亚	ONL Therapeutics, Inc.	2021-07-08
地图样萎缩	临床1期	新西兰	ONL Therapeutics, Inc.	2021-07-08
闭角型青光眼	临床前	-	ONL Therapeutics, Inc.	2023-11-20
视网膜色素变性	临床前	美国	ONL Therapeutics, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03780972 (ARVO2023)	临床1期	孔源性视网膜脱离 - 黄斑脱落 Fas-regulated cytokines	14	ONL1204	鬱獵網網憲鹽簾襯鹽遞(積範觸襯製蓋顧鬱網膚) = 襯觸製廠淵遞簾艱願襯鏇糧餘衊鹽願選簾窪積 (餘鑰餘鏇鏇願廠築簾顧 )	积极	2023-04-23